08:00 , Feb 22, 2016 |  BC Week In Review  |  Company News

Apeiron Biologics, Columbia University deal

The university’s Columbia Technology Ventures tech transfer office granted Apeiron exclusive, worldwide rights to develop and commercialize IP related to active cellular immunotherapies that inhibit casitas B cell lymphoma-b (Cbl-b) in T cells to...
07:00 , Mar 9, 2015 |  BC Week In Review  |  Clinical News

APN401: Phase I started

Apeiron began an open-label, dose-escalation, U.S. Phase I trial to evaluate IV APN401 every 14 days for up to 3 courses in >=16 patients with metastatic or inoperable solid tumors, including melanoma and renal cell...